Abstract
This study was designed to determine the protective effect of melatonin treatment against oxidative damage in rat brain induced by hyperhomocysteinemia (Hhcy). Oral administration of methionine and its degradation product, homocysteine (hcy), causes mild to moderate Hhcy. The major end-point of oxidative damage measured in this report was lipid peroxidation (LPO). The levels of malondialdehyde (MDA) were assayed as index of lipid peroxidation. The increase in lipid peroxidation was inhibited by melatonin. Rats were divided into seven groups: one was used as control and each remaining group was supplemented with methionine dissolved and added to the drinking water daily for 4 weeks (0.5, 1, 1.5, 2, 3g / kg BW). Additional groups of rats were given both melatonin (30 mg / kg BW) and methionine in drinking water daily. At the conclusion of the study, MDA levels were significantly increased in the brains of methioninetreated rats compared with control rats, whereas melatonin prevented the increases in MDA levels. Plasma hcy levels in animals treated with melatonin were significantly lower than those of controls. Melatonin lowered plasma hcy levels and could potentially be beneficial in prevention of neurodegeneration caused by mild hyperhomocysteinemia.
Keywords: hyperhomocysteinemia, homocysteine, methionine, melatonin, lipid, peroxidation, oxidative stress, malondialdeyde
Current Neurovascular Research
Title: Melatonin Prevents Hyperhomocysteinemia and Neural Lipid Peroxidation Induced by Methionine Intake
Volume: 2 Issue: 2
Author(s): Mounir Bouzouf, Francisco Martinez-Cruz, Patrocinio Molinero, Juan M Guerrero and Carmen Osuna
Affiliation:
Keywords: hyperhomocysteinemia, homocysteine, methionine, melatonin, lipid, peroxidation, oxidative stress, malondialdeyde
Abstract: This study was designed to determine the protective effect of melatonin treatment against oxidative damage in rat brain induced by hyperhomocysteinemia (Hhcy). Oral administration of methionine and its degradation product, homocysteine (hcy), causes mild to moderate Hhcy. The major end-point of oxidative damage measured in this report was lipid peroxidation (LPO). The levels of malondialdehyde (MDA) were assayed as index of lipid peroxidation. The increase in lipid peroxidation was inhibited by melatonin. Rats were divided into seven groups: one was used as control and each remaining group was supplemented with methionine dissolved and added to the drinking water daily for 4 weeks (0.5, 1, 1.5, 2, 3g / kg BW). Additional groups of rats were given both melatonin (30 mg / kg BW) and methionine in drinking water daily. At the conclusion of the study, MDA levels were significantly increased in the brains of methioninetreated rats compared with control rats, whereas melatonin prevented the increases in MDA levels. Plasma hcy levels in animals treated with melatonin were significantly lower than those of controls. Melatonin lowered plasma hcy levels and could potentially be beneficial in prevention of neurodegeneration caused by mild hyperhomocysteinemia.
Export Options
About this article
Cite this article as:
Bouzouf Mounir, Martinez-Cruz Francisco, Molinero Patrocinio, Guerrero M Juan and Osuna Carmen, Melatonin Prevents Hyperhomocysteinemia and Neural Lipid Peroxidation Induced by Methionine Intake, Current Neurovascular Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567202053586839
DOI https://dx.doi.org/10.2174/1567202053586839 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Small GTPase Signaling in Cell Physiology and Disease (Guest Editor: Crislyn DSouza-Schorey)]
Current Drug Targets Development of Anti-Atherosclerosis Therapy Based on the Inflammatory and Proliferative Aspects of the Disease
Current Pharmaceutical Design Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry Neuronal and Glial Cell Abnormality as Predictors of Progression of Diabetic Retinopathy
Current Pharmaceutical Design Clinical Applications of Nanotechnology in Atherosclerotic Diseases
Current Nanoscience Anti-Angiogenic Drugs in the Treatment of Metastatic Renal Cell Carcinoma: Advances in Clinical Application
Current Vascular Pharmacology Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Oral Targeting of Protein Kinase C Receptor: Promising Route for Diabetic Retinopathy?
Current Drug Delivery Understanding eNOS for Pharmacological Modulation of Endothelial Function: A Translational View
Current Pharmaceutical Design Why Do We Need New Gene Therapy Viral Vectors? Characteristics, Limitations and Future Perspectives of Viral Vector Transduction
Current Gene Therapy Tetracyclic Triterpenoids in Herbal Medicines and their Activities in Diabetes and its Complications
Current Topics in Medicinal Chemistry The Role of Adipocytokines in Atherogenesis and Atheroprogression
Current Drug Targets Pharmacotherapy in Systemic Lupus Erythematosus
Current Rheumatology Reviews Metabolism and the Paradoxical Effects of Arsenic: Carcinogenesis and Anticancer
Current Medicinal Chemistry Recent Developments in the Synthesis of Antitumor-active Glycyrrhetinic Acid Derivatives
Mini-Reviews in Organic Chemistry Polycystic Ovary Syndrome as a Proinflammatory State: The Role of Adipokines
Current Pharmaceutical Design Endogenous Agmatine Inhibits Cerebral Vascular Matrix Metalloproteinases Expression by Regulating Activating Transcription Factor 3 and Endothelial Nitric Oxide Synthesis
Current Neurovascular Research Uric Acid and Diabetes: Is there a Link?
Current Pharmaceutical Design Bergamot Juice Extract Inhibits Proliferation by Inducing Apoptosis in Human Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Advanced Glycation End Products (AGEs), Oxidative Stress and Diabetic Retinopathy
Current Pharmaceutical Biotechnology